Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib DDI with Hormonal Agents
NCT02093351Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of olaparib in solid tumor (3 cohorts), sponsored by AstraZeneca. Primary endpoints: Maximum Plasma Concentration at Steady State at Day 43 and Area Under the Plasma Concentration-Time Curve over the Dosing Interval at Day 43. Started Sep 2014; status: completed.
02
Drugs
olaparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02093351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02093351.